<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">CROSSLEY, RACHEL A.</style></author><author><style face="normal" font="default" size="100%">MATZ, ALYSSA</style></author><author><style face="normal" font="default" size="100%">DEW, TERRY</style></author><author><style face="normal" font="default" size="100%">KALINAUSKAS, ASHLEY</style></author><author><style face="normal" font="default" size="100%">FAUCETTE, NICOLE</style></author><author><style face="normal" font="default" size="100%">POFF, BRAD</style></author><author><style face="normal" font="default" size="100%">SILBART, LAWRENCE K.</style></author><author><style face="normal" font="default" size="100%">SUCKOW, MARK A.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1699-1703</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.13275</style></doi><volume><style face="normal" font="default" size="100%">39</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.</style></abstract></record></records></xml>